Azaya公司首席執行官Mike Dwyer近期接受SAN ANTONIO商業期刊採訪時指出，與北海康成共同開發ATI-1123是Azaya在美國以外開展新產品研發戰略合作夥伴的不二選擇
CANbridge, Azaya Ink Deal to Develop ATI-1123 for NSCLC
By Shannon Ellis, Staff Writer
SHANGHAI – Beijing newcomer CANbridge Life Sciences Ltd. has partnered with emerging nanotech specialist Azaya Therapeutics Inc., of San Antonio, to develop non-small-cell lung cancer (NSCLC) treatment ATI-1123 in China and North Asia. ATI-1123 is a liposomal formulation of docetaxel that has successfully completed U.S. FDA-approved Phase I trials for multiple solid tumor cancers.
Lung cancer is the most prevalent solid tumor cancer in China. The in-licensing deal for ATI-1123 marks CANbridge’s unoffi cial launch. Small in size, the 10-person team comes with a strong pedigree. Founder and CEO James Xue was the founding general manager of Genzyme China and is an early returnee who came back to China with an MBA and PhD from the U.S. Crystal Xu heads up clinical development and is the former director of medical and regulatory affairs at Genzyme.
For more, please read BioWorld Today VOLUME 24 , NO. 183, Page 7.